The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-alpha

International Immunopharmacology

Volumn 4, Issue 4, 2004, Pages 539-546

  Huang, Yin ^a   Chen, Zhi ^a   Zhou, Cheng ^a   Yao, Hangping ^a   Li, Minwei ^a   Xu, Chenghuai ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Dendritic cell; Differentiation; Interleukin 12; T cell stimulatory capacity; Thymosin alpha 1; Tumor necrosis factor alpha

Indexed keywords

CD4 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MIXED LYMPHOCYTE REACTION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; BONE MARROW CELLS; CELL DIFFERENTIATION; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-12; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; THYMOSIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16544385729     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.02.008     Document Type: Article

References (34)

1. Goldstein A.L. Clinical applications of thymosin alpha-1. Cancer Invest. 12:1994;545-547.
2. Li C.L., Zhang T., Saibara T., Nemoto Y. Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int. Immunopharmacol. 2:2002;39-46.
3. Ancell C.D., Phipps J., Young L. Thymosin alpha-1. Am. J. Health Syst. Pharm. 58:2001;879-885.
4. Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr. Opin. Investig. Drugs. 3:2002;698-707.
5. Pica F., Fraschetti M., Matteucci C., Tuthill C., Rasi G. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. 18:1998;3571-3578.
6. Low T.L., Thurman G.B., McAdoo M., McClure J.E., Rossio J.L.et al. The chemistry and biology of thymosin: I. Isolation, characterization, and biological activities of thymosin alpha-1 and polypeptide beta1 from calf thymus. J. Biol. Chem. 254:1979;981-986.
7. Hadden J.W., Saha A., Sosa M., Hadden E.M. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice. Int. J. Immunopharmacol. 17:1995;821-828.
8. Tzehoval E., Sztein M.B., Goldstein A.L. Thymosins alpha 1 and beta 4 potentiate the antigen-presenting capacity of macrophages. Immunopharmacology. 18:1989;107-113.
9. Sodhi A., Paul S. Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1. Int. Immunopharmacol. 2:2002;47-58.
10. di Francesco P., Gaziano R., Casalinuovo I.A., Belogi L., Palamara A.T.et al. Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments. Clin. Exp. Immunol. 97:1994;347-352.
11. Stefanini G.F., Foschi F.G., Castelli E., Marsigli L., Biselli M.et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology. 45:1998;209-215.
12. Bodey B., Bodey B. Jr., Siegel S.E., Kaiser H.E. Review of thymic hormones in cancer diagnosis and treatment. Int. J. Immunopharmacol. 22:2000;261-273.
13. Tomazic V.J., Novotny E.A., Ordonez J.V. Thymosin alpha 1-induced modulation of cellular responses and functional T-cell subsets in mice with experimental autoimmune thyroiditis. Cell. Immunol. 93:1985;340-349.
14. Zavaglia C., Severini R., Tinelli C. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe HBV-DNA-positive chronic hepatitis B. Dig. Dis. Sci. 45:2000;690-696.
15. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F.et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1999;1183-1186.
16. Maldonado-Lopez R., De Smedt T., Michel P., Godfroid J., Pajak B.et al. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:1999;587-592.
17. Voisine C., Hubert F.X., Trinite B., Heslan M., Josien R. Two phenotypically distinct subsets of spleen dendritic cells in rats exhibit different cytokine production and T cell stimulatory activity. J. Immunol. 169:2002;2284-2291.
18. Bottomly K. T cells and dendritic cells get intimate. Science. 283:1999;1124-1125.
19. McIlroy D., Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol. Immunother. 52:2003;583-591.
20. Palucka K.A., Taquet N., Sanchez-Chapuis F., Gluckman J.C. Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol. 160:1998;4587-4595.
21. Shimizu Y., Guidotti L.G., Fowler P., Chisari F.V. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161:1998;4520-4529.
22. Wang J., Saffold S., Cao X., Krauss J., Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161:1998;5516-5524.
23. Heystek H.C., Thierry A.C., Soulard P., Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and T(h)1-polarizing capacity. Int. Immunol. 15:2003;827-835.
24. Wang Z.Y., Morinobu A., Kawano S., Saegusa J., Wang B., Kumagai S. Gold sodium thiomalate suppresses the differentiation and function of human dendritic cells from peripheral blood monocytes. Clin. Exp. Rheumatol. 20:2002;683-688.
25. Kelleher P., Williams N.J., Knight S.C. Interleukin-12 administration in retroviral infection of mice increases the potential to produce functional dendritic cells from bone marrow stem cells. Immunol. Lett. 65:1999;51-54.
26. Sherman K.E., Jones C.C., Goldstein A.L., Naylor P.H. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol. 4:1991;195-199.
27. Sugahara S., Ichida T., Yamagiwa S., Ishikawa T., Uehara K.et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol. Res. 24:2002;346-354.
28. Liu Y.J. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 106:2001;259-262.
29. Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D.et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci U. S. A. 96:1999;1036-1041.
30. Trinite B., Voisine C., Yagita H., Josien R. A subset of cytolytic dendritic cells in rat. J. Immunol. 165:2000;4202-4208.
31. Mennechet F.J., Kasper L.H., Rachinel N., Li W., Vandewalle A., Buzoni-Gatel D. Lamina propria CD4+T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen. J. Immunol. 168:2002;2988-2996.
32. Shields P.L., Morland C.M., Salmon M., Qin S., Hubscher S.G., Adams D.H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163:1999;6236-6243.
33. Moser M., Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1:2000;199-205.
34. Wan Y., Lu L., Bramson J.L., Baral S., Zhu Q.et al. Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8(+) CTL in vivo. J. Immunol. 167:2001;5027-5033.